Cullinan Therapeutics, Inc. filings document formal disclosures for a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Recent Form 8-K reports furnish operating results and financial-condition updates, Regulation FD materials, and clinical disclosures tied to programs including CLN-978, CLN-049 and zipalertinib.
The filing record also covers corporate and governance matters, including definitive proxy disclosures on executive and director compensation, equity awards and shareholder voting matters. Material-event filings document portfolio and contractual actions, including the termination of an exclusive patent license related to CLN-617 through Cullinan Amber Corp.
Cullinan Therapeutics, Inc. reported that Chief Business Officer Corrine Savill received a grant of stock options covering 175,000 shares of common stock. The options have an exercise price of $0.00 per share and vest over four years in equal monthly installments of one forty-eighth of the grant.
Cullinan Therapeutics, Inc. reported that its Chief Financial Officer, Mary Kay Fenton, acquired new equity awards. She received a stock option for 137,500 shares of common stock and a separate award covering 68,750 shares of common stock. The shares underlying the restricted stock unit award vest annually over four years. The shares underlying the option vest over four years, with one forty-eighth of the optioned shares vesting in equal monthly installments until the fourth anniversary of the grant date.
Cullinan Therapeutics, Inc. reported that its Chief Scientific Officer, Jennifer Michaelson, received new equity awards. She was granted stock options for 115,000 shares at an exercise price of $0.0000 per share and 57,500 shares of common stock as an equity award.
According to the disclosure, the 57,500 common shares are in the form of restricted stock units that vest annually over four years. The 115,000 stock options vest over four years as well, with one forty-eighth of the options vesting in equal monthly installments until the fourth anniversary of the grant date.
Cullinan Therapeutics, Inc. received an amended Schedule 13G from Biotechnology Value Fund–affiliated entities reporting a large, primarily passive stake in its common stock. As of the close of business on December 31, 2025, the BVF funds and a managed account beneficially owned an aggregate of 5,918,481 shares of Cullinan common stock, or about 9.99% of the outstanding shares, including shares issuable from Series A preferred stock.
The BVF group holds 555,935 shares of Series A convertible preferred stock, which is convertible into 5,559,350 common shares at a 10:1 ratio, but a 9.99% “Conversion Blocker” currently limits conversion to 167,798 underlying shares. The reporting persons certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Cullinan, characterizing the position as a passive investment.
Cullinan Therapeutics Chief Scientific Officer Jennifer Michaelson reported an open-market sale of common stock. On February 12, 2026, she sold 416 shares of Cullinan Therapeutics, Inc. common stock at $12.03 per share.
According to the footnote, the sale was made to cover personal income tax obligations triggered by the vesting of restricted stock units. After this transaction, Michaelson directly beneficially owns 128,219 shares of Cullinan Therapeutics common stock.
The Vanguard Group reported beneficial ownership of 3,298,504 shares of Cullinan Therapeutics Inc common stock, representing 5.58% of the class. Vanguard has shared voting power over 377,729 shares and shared dispositive power over all 3,298,504 shares, with no sole voting or dispositive power.
The shares are held on behalf of Vanguard’s clients, who are entitled to dividends and sale proceeds, and no single other person has an interest exceeding 5% of the class. Vanguard states that the position was acquired and is held in the ordinary course of business and not for the purpose of influencing control of Cullinan Therapeutics.
Cullinan Therapeutics, Inc. insider trading report: Chief Scientific Officer Jennifer Michaelson reported a sale of company stock. On January 22, 2026, she sold 4,000 shares of Cullinan Therapeutics common stock at a price of $12.30 per share in an open-market transaction. The sale was carried out under a pre-established Rule 10b5-1 trading plan that was put in place on August 7, 2025, which is designed to allow insiders to sell shares according to a preset schedule. After this transaction, Michaelson directly beneficially owned 128,635 shares of Cullinan Therapeutics common stock.
Shareholder Jennifer Michaelson has filed a Rule 144 notice to sell up to 4,000 shares of common stock of the company trading under symbol CGEM. The proposed sale is to be executed through Morgan Stanley Smith Barney LLC, with an aggregate market value of $46,400 based on the price used in the notice, and an approximate sale date of January 22, 2026 on the NASDAQ. The filing notes that these 4,000 shares were acquired as restricted stock units from the issuer on December 11, 2023.
The notice also lists recent sales over the past three months for Michaelson’s account, including transactions of 1,345 shares for $13,458.34, 995 shares for $11,840.50, 2,148 shares for $26,592.24, and 4,000 shares for $49,200. Some of these trades are identified as being made under a Rule 10b5-1 trading plan. The filer represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
Cullinan Therapeutics reported preliminary cash, cash equivalents, short- and long-term investments, and interest receivable of $439.0 million as of December 31, 2025, and expects this cash runway to last into 2029 based on its current operating plan. The company emphasized that these figures are unaudited and may change once year-end financial closing procedures are complete.
Cullinan also outlined key 2026 milestones across its pipeline. For CLN-978 in multiple autoimmune diseases, it plans initial Phase 1 data readouts across rheumatoid arthritis, systemic lupus erythematosus, and Sjögren's disease between the second and fourth quarters of 2026. Velinotamig entered a Phase 1 study in China in December 2025, with initial data expected in the fourth quarter of 2026 to support global development.
In oncology, CLN-049 received Fast Track designation for relapsed/refractory AML, with further dose escalation updates and expansion cohorts planned through 2026, including preparation for an expected pivotal trial. For zipalertinib, co-developed with Taiho, a rolling NDA for relapsed EGFR ex20ins NSCLC is underway, with NDA completion targeted for the first quarter of 2026 and Cullinan eligible for up to $130.0 million in U.S. regulatory milestones plus 50% of any future pre-tax U.S. profits.
Cullinan Therapeutics Chief Scientific Officer, a reporting officer of the company, disclosed small open-market stock sales in December 2025. On 12/12/2025, 2,148 shares of common stock were sold at $12.38 to cover personal income tax obligations related to vesting restricted stock units.
On 12/15/2025, 995 shares were sold at $11.90 under a pre-arranged trading plan established pursuant to Rule 10b5-1 on August 7, 2025. After these transactions, the officer beneficially owns 136,878 shares of common stock, including 2,017 shares purchased through the 2021 Employee Stock Purchase Plan for the purchase period from January 1, 2025 through June 30, 2025.